Intermediate-Conductance Ca2+-Activated K+ Channel, KCa3.1, as a Novel Therapeutic Target for Benign Prostatic Hyperplasia

Susumu Ohya, Satomi Niwa, Yoshiyuki Kojima, Shoichi Sasaki, Motomu Sakuragi, Kenjiro Kohri, Yuji Imaizumi
J. Pharmacol. Exp. Ther. Aug 1, 2011
… …University and Taiho Pharmaceutical Co. Total RNA from human normal prostate was purchased from BD Biosciences (San Jose, CA) and BioChain (Hayward, CA) (21-50 years old, three distinct lot number samples). Total RNA extraction and reverse transcription were performed… …
Back to Top
x